Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
|
|
- Curtis Reeves
- 7 years ago
- Views:
Transcription
1 Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services ATTENTION DEFICIT HYPERACTIVITY DISORDER [ADHD] Introduction Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterised by persistent and pervasive pattern of inattention and/or hyperactivity and impulsiveness which can persist from childhood into adulthood and cause clinically significant impairments. Current management of ADHD includes a range of behavioural, social, psychological and pharmacological interventions and dietary advice. Pharmacological Treatment Drug treatment is not recommended as the first-line treatment for children and young people with ADHD but should be reserved for children and young people with severe symptoms or for those with moderate levels of impairment who have refused non-drug interventions, or whose symptoms have not responded sufficiently to educational interventions or group psychological treatment. Young people continuing ADHD treatment into adulthood should be assessed to establish the need for continuing pharmacological treatment. Pharmacological treatments for ADHD in adults and young people should be initiated only under the guidance of a specialist with expertise in ADHD, ideally as part of a multidisciplinary team; following thorough assessment and as part of a comprehensive treatment programme that addresses psychological, behavioural, educational and occupational needs. People with ADHD and concurrent substance misuse should be managed by specialists with expertise in both areas. Adults with ADHD should be offered pharmacological therapy as first-line treatment unless psychological approaches are preferred. Before initiating drug treatment, the diagnosis should be confirmed and a full assessment of ADHD and associated comorbidities done according to current national guidelines. Careful titration, monitoring and management of drug side effects is required. Cognitive behavioural therapy (CBT) may be considered when the service user has made an informed choice not to have drug treatment or drug treatment is partially effective or ineffective or if service user is intolerant to ADHD medications. Prescribing Advice Stimulant medications are the first-choice pharmacological treatments for ADHD in children, young people and adults. Methylphenidate and dexamfetamine are licensed for the treatment of ADHD in children and adolescents. Initiation in adults is off-label although treatment regimes are similar. Lisdexamfetamine (prodrug of dexamfetamine) may be prescribed by specialists only for ADHD in children aged 6 years and over when response to previous methylphenidate treatment is clinically inadequate. Atomoxetine is licensed for the treatment of ADHD in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. The choice of pharmacological treatment depends on a range of factors such as the presence of coexisting conditions, treatment side effects, risk of diversion and/or misuse or factors that may affect adherence and service user preference. If there is a choice of more than 1 appropriate drug, the product with the lowest cost (taking into account the cost per dose and number of daily doses) should be prescribed. Attention Deficit Hyperactivity Disorder Next Review: Jan
2 Prescribing Advice continued When prescribing medication off-label, it is the responsibility of the prescriber to determine the clinical need of the patient and the suitability of using medication outside its authorised indications. Informed consent should be obtained and documented. Before treatment, adults with ADHD should be offered written information about their condition and its assessment, potential benefits and adverse effects of medications, available services, psychological support and self-help. During the titration phase, doses should be gradually increased with monitoring until there is no further clinical improvement and side effects are tolerable. Consider dose reduction if side effects become troublesome. Dose titration should be slower if tics or seizures are present. Suspected side effects should be documented and reported via the Yellow Card Scheme, as appropriate. Following titration and dose stabilisation by a specialist (usually over 4 6 weeks), continued prescribing and monitoring may be transferred to GPs, under local shared care arrangements. If there is an adequate response, pharmacological treatment for ADHD should be continued for as long as it is clinically effective. If continued for more than a year, treatment should be monitored and reviewed annually as below. Methylphenidate should be stopped if there is no improvement in symptoms after appropriate adjustments in dosage over one month. It also needs to be stopped from time to time in those who do respond, to assess the patient's condition. Antipsychotics should not be used for treatment of ADHD in young people and adults. NB: Stimulants are controlled drugs and have the potential for misuse and diversion. The requirements of controlled drug legislation with respect to prescribing and supply of stimulants should be followed. Assessments and Monitoring NICE recommends that before starting drug treatment for adults with ADHD, a full assessment should be completed. This should include: full mental health and social assessment full history and physical examination, including: assessment of history of exercise syncope, undue breathlessness and other cardiovascular symptoms heart rate and blood pressure (plotted on a centile chart) weight and height family history of cardiac disease and examination of the cardiovascular system. an ECG if there is past medical or family history of serious cardiac disease, a history of sudden death in young family members or abnormal findings on cardiac examination risk assessment for substance misuse and drug diversion (when prescribing psychostimulants) Drug treatment should be reviewed annually. This should include: a comprehensive assessment of clinical need, benefits and side effects, taking into account the views of the person and, those of a spouse, partner, parent, close friends or carers wherever possible, and considering how these accounts may differ the effect of missed doses the effect of planned dose reductions taking into account brief periods of no treatment the preferred pattern of use coexisting conditions, with the person treated or referred if necessary the need for psychological, social and occupational support for the person and carer(s) Attention Deficit Hyperactivity Disorder Next Review: Jan
3 During treatment, monitor weight at 3 and 6 months from initiation and every 6 months thereafter. Strategies to reduce weight loss should be recorded in the care plan. Monitor heart rate and blood pressure at each dose change and routinely every 3 months; Reduce dose if clinically significant changes are noted. Relevant NICE Guidance NICE clinical guideline CG72. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. September Available at: Technology Appraisal 98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (including a review of guidance TA13). March Available at: NICE quality standards [QS39]. Attention deficit hyperactivity disorder. NICE Pathways. Attention deficit hyperactivity disorder. Local Shared Care Agreements SHARED CARE AGREEMENT between Mersey Care NHS Trust and Liverpool CCG Methylphenidate (Ritalin, Equasym, Concerta XL, Medikinet ) and Atomoxetine (Strattera ) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults 16 Years or older. Date Prepared: January 2013 Date for Review: April Attention Deficit Hyperactivity Disorder Next Review: Jan
4 Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults First Line: Relative Cost Notes Methylphenidate immediate release (IR) or modified release (M/R) (Schedule 2 controlled drug) Off-label for initiation in adults with ADHD Second Line: Relative Cost Notes Some formulations may be used as continuation treatment of ADHD in adolescents and adults. Dose titrated against symptoms and side effects over a 4 6 week period (see Appendix 2). Optimal doses and adequate therapeutic trial (6 weeks) are important to maximise response. Discontinue if there is no response after 1 month. Monitor, discuss and record side effects at each review or dose change. M/R preparations may improve adherence and limit misuse or diversion but are not bioequivalent. May affect performance of skilled tasks (e.g. driving); effects of alcohol may be unpredictable. Monitor weight at 3 and 6 months from initiation and every 6 months thereafter; if weight loss occurs, advise that medication should be taken with or after food and provide appropriate dietary advice. Heart rate and blood pressure should be monitored at each dose change and routinely every 3 months; reduce dose if clinically significant changes noted and refer to a physician. Discontinue treatment if psychotic symptoms emerge and carry out a full psychiatric assessment If anxiety symptoms develop, reduce dose, add antidepressants or switch to atomoxetine. If tics emerge, reduce dose or consider switching treatment to atomoxetine or stop treatment Atomoxetine Should be preferred if there are any contraindications to stimulant treatment; when treatment with methylphenidate has been ineffective, or not tolerated, in the presence of anxiety disorders or severe tics, or when there is a risk of misuse or diversion. Check history of cardiac problems or any significant cardiovascular concerns and carry out relevant investigations including ECG before starting treatment, as appropriate. Initial dose according to body weight, increased after 7 days to maintenance dose (see Appendix 2) Response to treatment should be assessed over the first 12 weeks. Monitor, discuss and record symptoms and side effects e.g. agitation, irritability, anxiety, suicidal thinking, self-harming and unusual changes in behaviour, particularly at initiation and after each dose change. Liver damage is a rare and idiosyncratic side effect of atomoxetine. Advise that this usually presents as abdominal pain, unexplained nausea, malaise, darkening of the urine or jaundice. Monitor for sexual dysfunction and dysmenorrhoea as side effects of atomoxetine Monitor weight at 3 and 6 months after initiation and every 6 months thereafter. If weight loss occurs, advise taking medication with or after food and provide appropriate dietary advice. Monitor heart rate and blood pressure at each dose change and routinely every 3 months; Reduce dose if clinically significant changes noted and refer to a physician. Attention Deficit Hyperactivity Disorder Next Review: Jan
5 Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults continued Second Line: Relative Cost Notes Alternative stimulants Dexamfetamine (Schedule 2 controlled drug) Lisdexamfetamine (Schedule 2 controlled drug) Other agents (Off-label use) Not currently licensed for the treatment of ADHD in adults. NICE advises use of dexamfetamine for refractory attention deficit hyperactivity disorder, if symptoms unresponsive to a maximum tolerated dose of methylphenidate or atomoxetine. Dose titrated to response over 4-6 weeks and given in divided doses see Appendix 1. Maintenance dose given in 2 4 divided doses Caution is required when prescribing to those likely to be at risk of stimulant misuse or diversion. Monitoring and management of side effects, as for methylphenidate (see above) It may be used as continuation ADHD treatment in adolescents and adults. Specialist only; Branded product so expensive; Can be initiated at 30mg daily with increases of 20mg at weekly intervals up to a maximum of 70mg. Lower abuse potential but may be less well tolerated than methylphenidate Relative Cost Black Triangle Product report all adverse effects to Notes Reserve for individuals who fail to respond to, or are intolerant of stimulants or atomoxetine Antidepressants - Limited evidence of effect for imipramine, venlafaxine and reboxetine; reboxetine preferred Also useful if anxiety symptoms are precipitated by stimulant Clonidine Limited evidence; common adverse effects of clonidine include sedation and reduced heart rate. cardiovascular examination and ECG should be carried out before starting treatment with clonidine Bupropion Limited evidence that use reduces symptoms but high risk of side effects; consider previous history of bipolar disorder and epilepsy; seek specialist advice Melatonin M/R May reduce sleep onset insomnia and improve duration of sleep in ADHD; side effects headache, dizziness and abdominal pain Not Recommended Relative Notes Cost Modafinil Limited evidence; Use now restricted to narcolepsy only due to safety concerns Antipsychotics - oral - There is no evidence that antipsychotics are of value in treatment of the symptoms of ADHD Omega 3 fatty acids There is no consistent evidence of effect Attention Deficit Hyperactivity Disorder Next Review: Jan
6 Treatment Resistant Attention Deficit Hyperactivity Disorder in Adults Strategy Relative Cost Notes Dose escalation - Increase dose of stimulant or atomoxetine; if improvement is only temporary, do not continue increasing the dose. Consider group or individual cognitive behavioural therapy (CBT) Switching - Seek specialist advice. Change the preparation or try alternative stimulant eg dexamfetamine. Change timing of administration. Consider alternative medication such as atomoxetine; or bupropion, clonidine or imipramine (consultant only).try alternative psychological interventions Combinations - Combinations of medications (eg atomoxetine and a stimulant) may be tried by ADHD specialists. Risk of psychosis and movement disorders Adding clonidine to existing stimulant therapy was associated with an increase in moderate to severe side effects, most notably sedation and drowsiness Treatment Resistant Attention Deficit Hyperactivity Disorder in Adults - Managing Co-morbid Conditions Condition Relative Cost Notes Depression - Treat depression with SSRIs first; atomoxetine or reboxetine preferred; check interactions and monitor side effects; CBT may be helpful. Anxiety/Agitation - Treat anxiety first; anxiety symptoms, may be precipitated by stimulants. Lower doses of stimulant medication and/or combined treatment with an antidepressant licenced for anxiety can be helpful. Monitor effect Psychotic Disorders - Use atomoxetine and antipsychotic medication; carefully monitor if using stimulants with antipsychotics Sleep Disorders - Sleep hygiene and behavioural therapy; adjust dose eg reduce evening dose of stimulant or administer earlier in the afternoon OR switch smimulants. Consider changing to atomoxetine. If hypnotic required, use zolpidem or consider off-label use of melatonin m/r (consultant initiation only). Attention Deficit Hyperactivity Disorder Next Review: Jan
7 Appendix 1 Strengths and Release Profiles for Different Formulations of Methylphenidate Methylphenidate generic and Ritalin, or Medikinet (Immediate Release IR) Concerta XL Modified release (M/R) Drug Name and Brand Equasym XL Modified release (M/R) Medikinet XL Modified release (M/R) Strengths 5mg, 10mg, 20mg 18mg, 27mg, 36mg, 54mg 10 mg, 20 mg, 30 mg 10 mg, 20 mg, 30 mg, 40 mg Product details IR 3-4 hours duration M/R hours duration M/R up to 8 hours duration M/R Up to 8 hours duration Release profile Peak plasma Concentration in 1-2 hours. 22% IR: 78% MR Initial peak plasma concentration in 1-2 hours. Second peak at 6-8 hours Formulation tablet Capsule shaped tablet containing two layers of drug. Outer layer (overcoat) released first, followed by gradual release of drug from inner core. Empty tablet shell excreted Administration details Tablets can be halved Tablet must be swallowed whole, not chewed, crushed or broken 30% IR: 70% MR Initial peak plasma concentration in 1-2 hours. Second peak at 4.5 hours Capsule containing two types of pellets/beads which allow immediate release of drug, followed by gradual release over the day. Capsule may be opened and contents mixed with soft foods.(stability unknown) Contents must be swallowed whole, not chewed, crushed or broken. 50% IR:50% MR Initial peak plasma concentration in 1-2 hours. Second phase of drug release 3 hours later resulting in a 3-4 hour plateau Capsule containing two types of pellets/beads which Allows immediate release of drug, followed by gradual release over the day. Capsule may be opened and contents mixed with soft foods.(stability unknown) Contents must be swallowed whole not chewed, crushed or broken. Ingestion with high fat content food delays absorption by approximately 1.5 hours. Attention Deficit Hyperactivity Disorder Next Review: Jan
8 Appendix 2 Doses and Side Effects of Drugs Used for ADHD Treatment Drug Name(s) Strengths Methylphenidate (Schedule 2 controlled drug) Immediate-release (IR) tablets (5mg, 10mg, 20mg) Not licensed in adults Ritalin (10mg) Medikinet (5mg, 10mg, 20mg) Off-label for use adults with ADHD. Modified-release (M/R) Concerta XL tablets (18mg, 27mg, 36mg) may be continued in adulthood if symptoms persist Medikinet XL Capsules (10mg, 20mg, 30mg, 40mg) may be continued in adulthood if symptoms persist Equasym XL Capsules (10mg, 20mg, 30mg) Not licensed in adults Dose May be given before breakfast and lunch. A later dose may be considered if the effect wears off in the evening causing rebound hyperactivity. In adults (>18 years) 5 mg up three times a day (as an immediate-release preparation), increased if necessary by 5 to 10 mg at weekly intervals to a maximum of 60 mg daily in divided doses (equivalent doses for M/R preparations). The dose should be titrated against symptoms and side effects over 4 6 weeks to a suitable maintenance dose. Up to 100mg daily may be given under specialist supervision. Modified-release preparations refer to BNF for specific advice on dosage for each brand M/R tablets must be swallowed whole, not chewed, crushed or broken. Modified release preparations of methylphenidate should be prescribed by brand name, as the different preparations are not interchangeable. Safety Precautions and Adverse Effects Contraindications and Cautions Hypersensitivity, glaucoma, phaechromocytoma, hyperthyroidism or thyrotoxicosis, preexisting cardiovascular or cerebrovascular disorders, vasculitis, pregnancy and breastfeeding; severe depression, anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, bipolar mania, schizophrenia, psychopathic/ borderline personality disorder. Diagnosis or history of severe and episodic (Type 1) Bipolar (affective) disorder (that is not well controlled) Also monitor for psychiatric disorders; anxiety or agitation; tics or a family history of Tourette syndrome; drug or alcohol dependence; epilepsy (discontinue if increased seizure frequency); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal. Should not be used in combination with or within 2 weeks of monoamine oxidase inhibitors Side effects Side effects include reduced appetite and weight, sleep disturbance, headaches, palpitations, nervousness, dysphoria, dry mouth, tachycardia, palpitations, increased blood pressure and heart rate (consider discontinuation or dose reduction), pruritis and rash; nasopharingitis, abdominal pain, diarrhoea, nausea and vomiting (may be alleviated by taking with food); dysphoria and agitation (may respond to dose reduction); psychotic reactions, such as hallucinations and delusional thinking; Tics; mania, seizures, and stroke have occurred, as has muscle damage with associated rhabdomyolysis and renal complications; syncope of cardiac origin requires specialist advice; blood dyscrasias (blood counts should be monitored periodically during prolonged therapy). Weight should be monitored during treatment with methylphenidate. Misuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events Methylphenidate can impair cognitive function and affect the person s ability to drive. Potential interaction with warfarin, antidepressants, antipsychotics, anticonvulsants, clonidine, alcohol and other sympathomimetics. Attention Deficit Hyperactivity Disorder Next Review: Jan
9 Appendix 2 continued Doses and Side Effects of Drugs Used for ADHD Treatment Drug Name Strengths Atomoxetine Strattera (Eli Lilly) 10mg, 18mg, 25mg, 40mg, 60mg or 80mg hard capsules. Indicated for the treatment of ADHD in children of 6 years and older, adolescents and adults as part of a comprehensive treatment programme. Dose Total daily dose may be administered as a single daily dose in the morning, with or without food or as equally divided doses in the morning and late afternoon or early evening. Adults (>18years) Starting dose (Maintain for at least 7 days) Maintenance dose <70kg 0.5mg/kg/day 1.2mg/kg/day >70kg 40mg/day 80mg to 100mg/day 120mg/day or (1.8mg/kg/day in patients <70kg) may be necessary in cases of poor response. A trial of 6 weeks on a maintenance dose should be allowed to evaluate the full effectiveness of atomoxetine. Dose should be reduced in liver failure (refer to BNF) Safety Precautions and Adverse Effects Contraindications and Cautions Contraindicated in hypersensitivity, closed angle glaucoma, severe cardiovascular or cerebrovascular disorders, pheochromocytoma, pregnancy and breast feeding Should not be used in combination with or within 2 weeks of monoamine oxidase inhibitors Prior to prescribing, take an appropriate medical history and assess baseline cardiovascular status, blood pressure and heart rate Caution in cardiovascular disease, cardiac abnormalities or other serious heart problems, QT prolongation, seizures, cerebrovascular disease, liver disease, aggressive behaviour, emotional lability, and prior history of psychotic illness or mania, suicidal ideation May affect performance of skilled tasks (e.g. driving); effects of alcohol unpredictable Side effects Headache, abdominal pain, decreased appetite and weight loss are most common; others - dyspepsia, nausea and vomiting, abdominal pain, anorexia and weight loss, fatigue, sleep disturbances, dizziness, cough, sinusitis or rhinorrhoea, urinary hesitancy or retention, sexual dysfunction, rashes, increased sweating, hot flushes, irritability, psychotic or manic symptoms (such as hallucinations, delusional thinking, mania, or agitation) and aggressive behaviour, hostility, or emotional lability; there have also been rare reports of severe hepatotoxicity - discontinue if jaundice or markedly increased liver enzyme values; increases in blood pressure and heart rate and orthostatic hypotension and syncope have been reported. Suicidal behaviour reported - monitor for signs of agitation, irritability, suicidal thought and self-harm and unusual changes in behaviour, particularly during the initial months of treatment or dose change; Seizures possible caution advised or avoid use. Check interactions with antidepressants, antipsychotics, CYP450 inhibitors etc. Attention Deficit Hyperactivity Disorder Next Review: Jan
10 Appendix 2 continued Doses and Side Effects of Drugs Used for ADHD Treatment Drug Proprietary Name(s) (Strengths) Dexamfetamine (Schedule 2 controlled drug) Dexedrine Off licence in adults Lisdexamfetamine (Schedule 2 controlled drug) Elvanse 30mg, 50mg, 70mg capsules, hard. Shire Pharmaceuticals Limited In adolescents whose symptoms persist into adulthood and who have shown clear benefit from treatment, it may be appropriate to continue treatment into adulthood. Dose In adults (>18 years), 5 mg twice daily, increased according to response to a maximum of 60 mg daily Initially 30 mg taken once daily in the morning, increased by 20 mg increments, at approximately weekly intervals to a maximum recommended dose of 70 mg/day; higher doses have not been studied. Dose adjustment may be required in the elderly Safety Precautions and Adverse Effects Contraindications and Cautions as for methylphenidate decreased appetite and weight; aggression, agitation, liable affect, mood swings, and depression; dizziness, dyskinesia, psychomotor hyperactivity, insomnia, night terrors, nervousness, restlessness, euphoria, fatigue, depression confusion, irritability, and headache; hypertension, tachycardia, cardiomyopathy, and myocardial infarction; dry mouth, diarrhoea, abdominal cramps, nausea, vomiting, and ischaemic colitis; sexual dysfunction; renal impairment; mydriasis; psychotic reactions (hallucinations, delusions, mania); very rarely, rhabdomyolysis, angle-closure glaucoma and sudden death Contraindications and Cautions hypersensitivity to sympathomimetic amines or relevant excipients; concomitant use of monoamine oxidase inhibitors (MAOI) or within 14 days of MAOI; hyperthyroidism or thyrotoxicosis; agitated states; symptomatic cardiovascular disease; moderate to severe hypertension; advanced arteriosclerosis; glaucoma; prescribe cautiously to people with a history of substance abuse or dependence; Cardiomyopathy has been reported with chronic amfetamine use; may exacerbate or induce psychosis and mania; stimulants may lower the seizure threshold Side effects Common adverse effects include nausea, vomiting, diarrhoea, decreased appetite, dry mouth, and abdominal cramps; aggression, headache, dizziness, drowsiness, sleep disturbances, and tics; weight loss and growth restriction; mydriasis, rash. Less common adverse effects include tachycardia, palpitations, hypertension, and cardiomyopathy; anxiety, paranoia, depression, dysphoria, depression, mania, hallucinations, and seizures; sexual dysfunction. Rarely, angle-closure glaucoma. For detailed information on contraindications, cautions, drug interactions, and adverse effects, see the electronic Medicines Compendium (emc) ( ) or the British National Formulary (BNF at Attention Deficit Hyperactivity Disorder Next Review: Jan
11 Appendix 3 Stimulant Dose Equivalents Methylphenidate is not licensed for use in adults with attention deficit hyperactivity disorder (ADHD) and hyperkinetic disorders (HKD). Manufacturers state that the maximum daily dose is 60 mg per day for Ritalin, Equasym and Medikinet. For Concerta XL the maximum dose is 54mg. However, NICE guidelines defines that methylphenidate can be use in adults with ADHD and the dose should be increased according to response up to a maximum of 100 mg/day [CG ]. For Equasym XL and Medikinet XL brands, methylphenidate IR tablets are equipotent. So, the dose can be prescribed on a 1:1 basis. Modifiedrelease preparations should usually be given as a single dose in the morning and no more than twice daily. For Concerta XL, the manufacturer only provides the dose equivalents for those who are currently taking methylphenidate three times daily at doses of 15 to 45 mg/day. Doses of modified release preparations may vary according to brand chosen. See table below. Stimulant Dose Equivalents Methylphenidate IR Concerta XL Equasym XL Medikinet XL (in divided doses) 5 mg mg - 10 mg 10 mg 15 mg 18 mg once daily mg 20 mg 20 mg 30 mg 36 mg once daily 30 mg 30 mg mg 45 mg 54 mg once daily mg 72 (*Licensed up to 54 mg) 60 mg - * Adapted from NICE ADHD guidelines. Direct conversions for doses beyond maximum licensed doses are not provided in the literature. Attention Deficit Hyperactivity Disorder Next Review: Jan
12 References 1. NICE clinical guideline CG72. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. Available at: 2. Technology Appraisal 98 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (including a review of guidance TA13) Consensus Group. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology.. J Psychopharmacol. Feb 2014: NICE. Attention deficit hyperactivity disorder Evidence Update July NICE advice [ESUOM8]. Attention deficit hyperactivity disorder in children and young people: clonidine. Published date: April NICE advice [ESNM19]. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate. May NICE advice [ESUOM2]. Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin January MHRA (2009) Methylphenidate: updated guidance on safe and effective use in ADHD. Drug Safety Update 2(8), MHRA (2009) Atomoxetine: risk of psychotic or manic symptoms. Drug Safety Update 2(8), MHRA (2012) Atomoxetine (Strattera [black triangle]): increases in blood pressure and heart rate - new contraindications, warnings, and advice for monitoring. Drug Safety update 5(6), A Scottish Intercollegiate Guidelines Network 2009: Management of attention deficit and hyperkinetic disorders in children and young people at: Kooij et al. European consensus statement on diagnosis and treatment of adult ADHD: The European network Adult ADHD. BMC Psychiatry 2010: 10: 67 Attention Deficit Hyperactivity Disorder Next Review: Jan
13 13. NICE CKS. Attention deficit hyperactivity disorder. Last revised in May 2014 Available at: Pan Mersey Melatonin M/R statement Adult ADHD Self-Report Scales. Available at: Manufacturer summaries of product characteristics (SPCs), various. Available at: The United Kingdom Adult ADHD Network (UKAAN) at: ADHD Consultants Mersey Care Specialist in ADHD (expert opinion). Attention Deficit Hyperactivity Disorder Next Review: Jan
Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72
Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2008. All rights reserved. Last updated February 2016 Contents
More information3Ts Formulary Shared Care Guideline
Methylphenidate, Atomoxetine and Lisdexamfetamine (TLS Amber) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents AREAS OF RESPONSIBILITY FOR THE SHARING OF
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationSTRATTERA (Stra-TAIR-a)
1 PV 5859 AMP MEDICATION GUIDE STRATTERA (Stra-TAIR-a) (atomoxetine) Capsules Read the Medication Guide that comes with STRATTERA before you or your child starts taking it and each time you get a refill.
More informationGMMMG Interface Prescribing Subgroup. Shared Care Template
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.
More informationStimulants and Nonstimulants for ADHD
Stimulants and Nonstimulants for ADHD Stimulants Adderall and Adderall XR (amphetamine mixtures) Concerta (methylphenidate, extended release) Daytrana (methylphenidate topical patch) Dexedrine and Dexedrine
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationExtended-release methylphenidate (Concerta) for attention deficit hyperactivity disorder
for attention deficit hyperactivity disorder (meth-il-fen-i-date) Summary is one of two available controlled-release formulations of the psychostimulant methylphenidate (immediate-release methylphenidate
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More informationPaxil/Paxil-CR (paroxetine)
Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except
More informationMEDICATION FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
CONTINUING CARE GUIDELINES AND INFORMATION FOR SECONDARY CARE AND GENERAL PRACTITIONERS MEDICATION FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) Date of implementation November 2013
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationMEDICATION GUIDE. Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR)
MEDICATION GUIDE Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR) Read this Medication Guide carefully before you start taking bupropion hydrochloride extendedrelease
More informationDiagnosis and management of ADHD in children, young people and adults
Issue date: September 2008 Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults NICE clinical guideline 72 Developed by the National Collaborating
More informationUpdate on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice
Update on guidelines on biological treatment of depressive disorder Dr. Henry CHEUNG Psychiatrist in private practice 2013 update International Task Force of World Federation of Societies of Biological
More informationMEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:
MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationADHD PRACTISE PARAMETER. IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY
ADHD PRACTISE PARAMETER IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY Similar type of idea Similar document Similar document AACAP document Neurobiological condition
More informationCRITERIA FOR DIAGNOSIS AND MANAGEMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS
CRITERIA FOR DIAGNOSIS AND MANAGEMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS For the purpose of this document adults are considered to be persons who are 18 years or over. Separate criteria
More informationThe following is a sample of psychotropic drug warnings that drug regulatory agencies
Chronology of International Drug Regulatory Agency Warnings about Psychotropic Drugs The following is a sample of psychotropic drug warnings that drug regulatory agencies around the world have issued.
More informationADHD: what treatments work?
Patient information from the BMJ Group ADHD: what treatments work? Caring for a child who has attention deficit hyperactivity disorder (ADHD) can put a strain on you and your family. If your child has
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationReference ID: 2914553
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STRATTERA safely and effectively. See full prescribing information for STRATTERA. STRATTERA (atomoxetine
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants) and other psychiatric
More informationAutism Spectrum Disorders and Comorbid Behavioral Health Symptoms
Autism Spectrum Disorders and Comorbid Behavioral Health Symptoms Cynthia King, MD Child and Adolescent Psychiatrist Associate Professor of Psychiatry UNMSOM Psychopharmacologic and Alternative Medicine
More informationWellbutrin (bupropion)
Wellbutrin (bupropion) FDA ALERT [09/2007] - Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents,
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationMEDICATION GUIDE ZYBAN (zi ban) (bupropion hydrochloride) Sustained-Release Tablets
GlaxoSmithKline Research Triangle Park, NC 27709 2013, GlaxoSmithKline group of companies. All rights reserved. ZYB:XPI MEDICATION GUIDE ZYBAN (zi ban) (bupropion hydrochloride) Sustained-Release Tablets
More informationAntipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers
SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationAmphetamines Addiction
Introduction Amphetamines, which are classified as stimulants, work by using the dopamine reward system of the brain. When these drugs are used, the user s central nervous system is simulated which causes
More informationMedication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules
Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Read this Medication Guide before you start taking EQUETRO and each time you get a refill. There may be new information. This
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationMEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS. Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D.
MEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D. Introduction Tourette Syndrome (TS) or Tourette s Disorder
More informationMajor Depression. What is major depression?
Major Depression What is major depression? Major depression is a serious medical illness affecting 9.9 million American adults, or approximately 5 percent of the adult population in a given year. Unlike
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationShared Care Protocol for the Prescription of Memantine for Alzheimer s disease
Shared Care Protocol for the Prescription of Memantine for Alzheimer s disease 1. REFERRAL CRITERIA Patients of any age that are suspected to be suffering from moderate to severe Alzheimer s disease will
More informationMOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationBRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS
BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationObsessive Compulsive Disorder: a pharmacological treatment approach
Obsessive Compulsive Disorder: a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital
More informationMEDICATION GUIDE WELLBUTRIN XL * (WELL byu-trin) (bupropion hydrochloride extended-release tablets)
MEDICATION GUIDE WELLBUTRIN XL * (WELL byu-trin) (bupropion hydrochloride extended-release tablets) Read this Medication Guide carefully before you start using WELLBUTRIN XL and each time you get a refill.
More informationNew Developments in the Treatment of ADHD in Children: How the Pharmacist and Pharmacy Technician Can Impact Care
New Developments in the Treatment of ADHD in Children: How the Pharmacist and Pharmacy Technician Can Impact Care Post-Test/Rationale EDUCATIONAL OBJECTIVES Upon completion of this activity, participants
More informationCOUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationMEDICATION INFORMATION FOR PARENTS - STIMULANTS
MEDICATION INFORMATION FOR PARENTS - STIMULANTS Patient Name is taking Medication Doctor's name If you have any questions about this medicine, please call the office at 631-3510. General Information about
More informationLeading European Psychiatrists, Janssen-Cilag and Scientific Fraud
Concerta for adults Leading European Psychiatrists, Janssen-Cilag and Scientific Fraud December 9, 2011 How could leading European psychiatrists claim that the ADHD drug Concerta was safe and worked fantastically
More informationUse these talking points to help start a conversation with your healthcare professional
My Discussion Guide Use these talking points to help start a conversation with your healthcare professional Questions list: How can I know if I have ADHD? Can my ADHD be managed? What is Strattera and
More informationMEDICATION GUIDE. TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets
MEDICATION GUIDE TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets Read this Medication Guide before you start taking TRINTELLIX and each time you get a refill. There may be new information. This information
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationAcetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review
More informationClinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
More informationNovartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)
Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI) Highlights from Prescribing Information - the link to the full text PI is as follows: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationDrugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
More informationClinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90
Depression in adults: recognition and management Clinical guideline Published: 28 October 2009 nice.org.uk/guidance/cg90 NICE 2009. All rights reserved. Last updated April 2016 Your responsibility The
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationNEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate.
NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate. PRESENTATION Eye Drops: NAPHCON-A Eye Drops are a combination of an antihistamine (pheniramine maleate) and a decongestant
More informationGalantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease
IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl
More informationSIGN. Management of attention deficit and hyperkinetic disorders in children and young people. October 2009. A national clinical guideline
SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines - click here to complete our survey 112 Management of attention deficit and
More informationTrileptal (Oxcarbazepine)
Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine
More informationDepression in adults with a chronic physical health problem
Depression in adults with a chronic physical health problem Treatment and management Issued: October 2009 NICE clinical guideline 91 guidance.nice.org.uk/cg91 NICE has accredited the process used by the
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Librium 10mg Hard capsule Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 10 mg of chlordiazepoxide hydrochloride. Excipients:
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationMedication Guide. Cymbalta. (duloxetine delayed-release capsules)
Medication Guide 1 Cymbalta [sim-ball-tah] (duloxetine delayed-release capsules) Read this Medication Guide before you start taking Cymbalta and each time you get a refill. There may be new information.
More informationThis controlled document shall not be copied in part or whole without the express permission of the author or the author s representative.
This document can be made available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on 01224 551116 or 01224 552245. This controlled document
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationDementa Formulary Guidance [v1.0]
Dementa Formulary Guidance [v1.0] 1. Introduction These Guidelines are intended for routine use. However there will be instances where they are not suitable for the patient you are managing, where more
More informationBenzodiazepine Detoxification and Reduction of Long term Use
Benzodiazepine Detoxification and Reduction of Long term Use Malcolm Lader 1 Model of general drug misuse and dependence. Tactical interventional options Social dimension Increasing breaking of social
More informationMedication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets
Medication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets What is the most important information I should know about LATUDA? LATUDA may cause serious side effects, including: 1. Increased
More informationRemeron (mirtazapine)
Remeron (mirtazapine) FDA ALERT [07/2005] Suicidal Thoughts or Actions in Children and Adults Patients with depression or other mental illnesses often think about or attempt suicide. Closely watch anyone
More informationClinical guideline Published: 29 November 2005 nice.org.uk/guidance/cg31
Obsessive-compulsive e disorder and body dysmorphic disorder: treatment Clinical guideline Published: 29 November 2005 nice.org.uk/guidance/cg31 NICE 2005. All rights reserved. Contents Introduction...
More information`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå. aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí=
`çããçå=jéåí~ä= aáëçêçéêëw=^åñáéíó=~åç= aééêéëëáçå aêk=`=f=lâçåü~ jéçáå~ä=aáêéåíçê lñäé~ë=kep=cçìåç~íáçå=qêìëí= Overview: Common Mental What are they? Disorders Why are they important? How do they affect
More informationPost-traumatic stress disorder overview
Post-traumatic stress disorder overview A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
More informationInformation for Prescribing Anti-dementia Drugs. November 2012
Information for Prescribing Anti-dementia Drugs The aim of this document is to provide information about the prescribing of anti-dementia medication for adult patients with dementia following an assessment
More informationMedications Used in the Management of Disruptive Behavior Disorders
The following medication chart is provided as a brief guide to some of the medications used in the management of various behavior disorders, along with their potential benefits and possible side effects.
More informationMEDICATION GUIDE. Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets
MEDICATION GUIDE Tranxene* (TRAN-zeen) T-TAB (clorazepate dipotassium) tablets Read this Medication Guide before you start taking TRANXENE and each time you get a refill. There may be new information.
More informationPsychosis and schizophrenia in children and young people
Psychosis and schizophrenia in children and young people Recognition and management Issued: January 2013 NICE clinical guideline 155 guidance.nice.org.uk/cg155 NICE has accredited the process used by the
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationFeeling Moody? Major Depressive. Disorder. Is it just a bad mood or is it a disorder? Mood Disorders. www.seclairer.com S Eclairer 724-468-3999
Feeling Moody? Is it just a bad mood or is it a disorder? Major Depressive Disorder Prevalence: 7%; 18-29 years old; Female>Male DDx: Manic episodes with irritable mood or mixed episodes, mood disorder
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationUpdate and Review of Medication Assisted Treatments
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationMemantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
More informationMental Health and Addictions, Practical Information for Supporting Students with Mental Health Challenges. May 2013
Mental Health and Addictions, Practical Information for Supporting Students with Mental Health Challenges May 2013 Parts of this presentation are adapted from the Mental health awareness workshop developed
More informationStep 4: Complex and severe depression in adults
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
More informationAmendments to recommendations concerning venlafaxine
Amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised prescribing advice for venlafaxine*. This amendment brings the guideline into line with the new advice but does
More informationDepre r s e sio i n o i n i a dults Yousuf Al Farsi
Depression in adults Yousuf Al Farsi Objectives 1. Aetiology 2. Classification 3. Major depression 4. Screening 5. Differential diagnosis 6. Treatment approach 7. When to refer 8. Complication 9. Prognosis
More information